The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The development of IBD‐related colorectal cancer (CRC), chronic inflammation is a major risk factor for gastrointestinal malignancies development in IBD patients.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [138]
In the citing paper
“There has been evidence over the decade that show a link between chronic intestinal inflammation and CRC thorough a series of events; from the development of early dysplasia to low grade dysplasia to high‐grade dysplasia to eventually converting to invasive adenocarcinoma.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [138]
In the citing paper
“Currently, therapies to treat IBD diminish the mucosal inflammatory response.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., & Zhao, L. (2012) · The ISME Journal · doi:10.1038/ismej.2011.109 · Cited by 1,287
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Primary sclerosing cholangitis: diagnosis, prognosis, and management
Singh, S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.016 · Cited by 119
Research works printed but not linked: 57
- 10.1053/j.gastro.2011.10.001 · DOI · Paper page
- 10.1053/j.gastro.2005.12.035 · DOI
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535. · DOI
- 10.1053/j.gastro.2011.01.057 · DOI
- 10.1038/ajg.2009.760 · DOI
- 10.1056/NEJMra1403718 · DOI
- 10.1056/NEJM199011013231802 · DOI
- 10.1152/ajpgi.00079.2004 · DOI
- Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611-1620. · DOI
- Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993;104:1633-1639. · DOI
- Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-3337.
- Aust DE, Terdiman JP, Willenbucher RF, Chang CG, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002;94:1421-1427. · DOI
- Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000;60:4864-4868.
- 10.1097/MIB.0000000000000236 · DOI
- 10.1053/j.gastro.2014.01.001 · DOI
- 10.1016/j.molcel.2014.03.039 · DOI
- 10.1101/gr.126516.111 · DOI · Paper page
- 10.1111/j.1572-0241.2005.00287.x · DOI
- 10.1097/MIB.0000000000000112 · DOI
- 10.3109/00365521.2014.946085 · DOI
- 10.1016/j.semcancer.2008.10.002 · DOI
- 10.1126/science.1114233 · DOI
- 10.1038/nrc2628 · DOI
- 10.1136/gutjnl-2011-301133 · DOI
- Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-219. · DOI · Paper page
- 10.1093/aje/kws375 · DOI
- 10.1136/gutjnl-2013-305763 · DOI
- 10.1001/jama.2014.5613 · DOI
- 10.1016/S0140-6736(09)61302-7 · DOI
- 10.1111/j.1572-0241.1999.01530.x · DOI
- Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-1087. · DOI
- 10.1002/ibd.22889 · DOI
- 10.1080/10428190801911662 · DOI
- 10.1016/j.cgh.2010.09.016 · DOI
- 10.1016/j.cgh.2009.11.024 · DOI
- 10.1053/j.gastro.2012.05.004 · DOI
- 10.1053/j.gastro.2011.06.050 · DOI
- 10.1016/j.cgh.2013.04.033 · DOI
- Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67:1167-1198. · DOI
- Penn I. Kidney transplantation in patients previously treated for renal carcinomas. Transpl Int 1993;6:350. · DOI
- 10.1016/j.cgh.2015.07.037 · DOI
- 10.1002/acr.20129 · DOI
- 10.1186/ar2904 · DOI
- 10.1016/j.cgh.2012.06.016 · DOI
- 10.1016/j.crohns.2013.12.022 · DOI
- Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:835-840. · DOI
- Naito A, Mizushima T, Takeyama H, Sakai D, Uemura M, Kudo T, Nishimura J, Shinzaki S, Hata T, Sato T. Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer. Hepatogastroenterology 2014;61:942-946.
- 10.1200/JCO.2007.11.2136 · DOI
- 10.1016/j.lungcan.2009.06.020 · DOI
- Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25.
- 10.1016/j.bbrc.2011.03.051 · DOI
- 10.1002/art.30247 · DOI
- 10.1007/s00262-008-0653-8 · DOI
- 10.1002/cncr.27969 · DOI
- 10.1016/j.suronc.2013.08.002 · DOI
- 10.1016/j.cgh.2014.02.026 · DOI
- 10.1111/apt.13466 · DOI
Cited by
Sorted by citations
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
Lavelle, J., Storan, D., Eswara Murthy, V., De Dominicis, N., Mulcahy, H. E., & McHugh, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102757 · Cited by 23
“The impact of IBD is wide-ranging and symptoms include diarrhoea, rectal bleeding, unintended weight loss, and fatigue, while IBD also confers an increased risk of certain cancers [1,2].”
BackgroundThe Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease
Fanizza, J., D’Amico, F., Lauri, G., Martinez-Dominguez, S. J., Allocca, M., Furfaro, F., Zilli, A., Fiorino, G., Parigi, T. L., Radice, S., et al. (2024) · Immunotherapy · doi:10.2217/imt-2023-0116 · Cited by 16
Metadata
- Authors
- Axelrad, J. E., Lichtiger, S., & Yajnik, V.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 22
- Issue
- 20
- Pages
- 4794
- ISSN
- 1007-9327
- Cited by
- 431
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
